LMR Partners LLP Purchases Shares of 153,324 DexCom, Inc. (NASDAQ:DXCM)

LMR Partners LLP acquired a new stake in DexCom, Inc. (NASDAQ:DXCM) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 153,324 shares of the medical device company’s stock, valued at approximately $11,924,000.

A number of other institutional investors also recently made changes to their positions in DXCM. Private Trust Co. NA lifted its stake in DexCom by 266.3% in the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company’s stock worth $26,000 after purchasing an additional 245 shares during the last quarter. Optiver Holding B.V. bought a new position in DexCom in the 4th quarter worth $33,000. TD Private Client Wealth LLC lifted its position in shares of DexCom by 62.8% in the 4th quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company’s stock worth $34,000 after purchasing an additional 167 shares during the period. Larson Financial Group LLC boosted its stake in shares of DexCom by 40.5% during the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company’s stock valued at $37,000 after purchasing an additional 137 shares in the last quarter. Finally, Heck Capital Advisors LLC purchased a new position in shares of DexCom during the fourth quarter valued at about $38,000. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Insider Activity at DexCom

In other DexCom news, CEO Kevin R. Sayer sold 32,498 shares of the firm’s stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total transaction of $2,287,209.24. Following the completion of the transaction, the chief executive officer now owns 372,029 shares in the company, valued at $26,183,401.02. This trade represents a 8.03% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, EVP Jereme M. Sylvain sold 7,000 shares of DexCom stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $73.83, for a total value of $516,810.00. Following the completion of the sale, the executive vice president now directly owns 135,482 shares in the company, valued at approximately $10,002,636.06. The trade was a 4.91% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 66,926 shares of company stock valued at $4,734,384. Corporate insiders own 0.32% of the company’s stock.

Analyst Ratings Changes

Several analysts have commented on DXCM shares. Piper Sandler lowered their price objective on shares of DexCom from $100.00 to $90.00 and set an “overweight” rating for the company in a report on Friday, May 2nd. Morgan Stanley increased their target price on DexCom from $75.00 to $82.00 and gave the stock an “equal weight” rating in a research report on Friday, February 14th. Baird R W upgraded DexCom from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 16th. Barclays upped their price target on DexCom from $90.00 to $93.00 and gave the stock an “equal weight” rating in a research note on Monday, May 5th. Finally, Citigroup increased their price objective on DexCom from $101.00 to $104.00 and gave the stock a “buy” rating in a report on Tuesday, March 4th. Five analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $98.11.

DexCom Trading Down 0.8%

DexCom stock opened at $84.66 on Monday. The business’s fifty day moving average is $71.08 and its 200 day moving average is $77.22. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28. The stock has a market capitalization of $33.20 billion, a PE ratio of 59.20, a price-to-earnings-growth ratio of 2.30 and a beta of 1.43. DexCom, Inc. has a one year low of $57.52 and a one year high of $132.26.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Thursday, May 1st. The medical device company reported $0.32 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.01). DexCom had a net margin of 14.29% and a return on equity of 30.14%. The firm had revenue of $1.04 billion for the quarter, compared to the consensus estimate of $1.02 billion. During the same quarter in the prior year, the firm earned $0.32 earnings per share. The company’s revenue for the quarter was up 12.5% compared to the same quarter last year. On average, sell-side analysts predict that DexCom, Inc. will post 2.03 EPS for the current year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.